Release Date: 14-Jul-2024
Protein disulfide isomerase (PDI), a multifunctional enzyme primarily located in the endoplasmic reticulum, plays a crucial role in protein folding, assembly, and quality control. Its normal functions include catalyzing the formation, reduction, and isomerization of disulfide bonds within proteins, ensuring their proper folding and functionality. However, dysregulated expression or activity of PDI has been implicated in a wide range of diseases, making it an attractive therapeutic target for intervention.
In cancer, PDI is involved in tumor growth, metastasis, and resistance to chemotherapy. Elevated levels of PDI have been observed in various cancer types, where it promotes tumor cell proliferation, survival, and angiogenesis. Moreover, PDI facilitates the folding and secretion of proteins involved in cancer progression, such as growth factors, cytokines, and cell surface receptors. Targeting PDI offers a promising strategy for disrupting these pro-tumorigenic pathways and sensitizing cancer cells to chemotherapy.
PDI has been associated with neurodegenerative disorders due to its involvement in the misfolding and aggregation of disease-specific proteins. Additionally, PDI contributes to the regulation of blood coagulation and thrombosis, along with modulating vascular function and inflammation. Imbalances in PDI function have been connected to the onset of cardiovascular diseases, presenting opportunities to regulate PDI activity for disease management.
Despite its therapeutic potential, developing specific inhibitors against PDI has been challenging due to its multifunctional nature and essential role in normal cellular processes. However, Oregon Therapeutics has made a historic entry into the market with its lead candidate XCE853, a first-in-class PDI inhibitor, targeting novel and targeted cancer indications. XCE853 demonstrates potent activity in killing cancer cells resistant to current chemotherapeutic drugs, addressing a critical unmet medical need in oncology.
Oregon Therapeutics is focusing on pancreatic cancer as the first indication for XCE853, given the urgent need for effective treatments in this aggressive malignancy. Preclinical data suggest that XCE853 holds promise in pancreatic cancer, where resistance to standard therapies poses a significant challenge to patient outcomes. Moreover, XCE853 shows potential in other cancer types, including ovarian, prostate, colorectal, and non-small cell lung cancers, indicating broader applicability across solid tumors.
In March 2024, Oregon Therapeutics announced a strategic AI-driven collaboration with Lantern Pharma to optimize the development of XCE853 using Lantern's proprietary RADR AI platform. This collaboration aims to uncover biomarkers and efficacy-associated signatures of XCE853 across solid tumors, facilitating precision development and personalized treatment approaches. Lantern Pharma's RADR AI platform will leverage in vitro and in vivo data to advance XCE853 development in a highly targeted manner, informing disease indications, biomarker signatures, and potential combination therapies with other approved cancer drugs.
The future implications of XCE853 and the broader class of PDI inhibitors are significant. By targeting PDI-mediated pathways involved in cancer progression and therapeutic resistance, these inhibitors offer new opportunities for improving patient outcomes and overcoming treatment challenges in oncology. Moreover, the integration of AI-driven approaches, such as Lantern Pharma's RADR platform, holds promise for accelerating drug development, identifying predictive biomarkers, and informing personalized treatment strategies. As research advances and clinical trials progress, PDI inhibitors like XCE853 have the potential to reshape the landscape of cancer therapy, offering new hope for patients with advanced and refractory malignancies.
For Clinical Trials Information Contact